• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mind Medicine Mindmed Inc (NQ: MNMD )

    6.140 -0.160 (-2.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mind Medicine Mindmed Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    31 32 Next >
    Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows
    Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined... 
    Via Benzinga
    NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
    NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
    Via Benzinga
    MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
    MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders,  
    Via Benzinga
    MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    Analyst Expectations for Mind Medicine's Future
    Via Benzinga
    What 9 Analyst Ratings Have To Say About Mind Medicine
    Via Benzinga
    Mind Science Targeting Big Brains and Portfolios
    Via AB Newswire
    Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
    Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    6 Largest Psychedelic Compound-Based R & D Stocks In Decline
    The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
    Via Talk Markets
    The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
    The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
    Via Talk Markets
    Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
    Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
    Via Benzinga
    August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
    The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
    Via Talk Markets
    Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
    Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
    Via Benzinga
    MindMed to Participate at September Investor Conferences
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
    Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
    Via Talk Markets
    Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
    Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
    Via Benzinga
    Topics Cannabis Economy
    Exposures Cannabis Interest Rates
    Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
    The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
    Via Talk Markets
    MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
    Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative... 
    Via Benzinga
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
    Via Benzinga
    MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
    The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
    Via Talk Markets
    MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead
    Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this: 
    Via Benzinga
    MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
    From MindMed
    Via Business Wire
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
    Via Benzinga
    MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
    From Mind Medicine (MindMed) Inc
    Via Business Wire
    MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
    All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
    Via Talk Markets
    Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
    UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
    Via Benzinga
    Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
    EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
    Via FinancialNewsMedia
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    31 32 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.